نتایج جستجو برای: sitagliptin phosphate

تعداد نتایج: 105931  

2015
Hsin Ying Lu Chun Yao Huang Chun Ming Shih Wei Hung Chang Chein Sung Tsai Feng Yen Lin Chun Che Shih

Abdominal aortic aneurysm (AAA) is a life-threatening situation affecting almost 10% of elders. There has been no effective medication for AAA other than surgical intervention. Dipeptidyl peptidase-4 (DPP-4) inhibitors have been shown to have a protective effect on cardiovascular disease. Whether DPP-4 inhibitors may be beneficial in the treatment of AAA is unclear. We investigated the effects ...

2013
Jin Lu Jiajie Zang Huihua Li

BACKGROUND The effect of metformin, pioglitazone and sitagliptin on β-cell function in the treatment of type 2 diabetes is controversial. Therefore, we performed a systematic review and meta-analysis to obtain a better understanding in the β-cell effects of metformin, pioglitazone and sitagliptin. METHODS We searched Pubmed and the Cochrane Center Register of Controlled Trials to identify rel...

Journal: :The Journal of clinical endocrinology and metabolism 2006
Gary A Herman Arthur Bergman Catherine Stevens Paul Kotey Bingming Yi Peng Zhao Bruno Dietrich George Golor Andreas Schrodter Bart Keymeulen Kenneth C Lasseter Mark S Kipnes Karen Snyder Deborah Hilliard Michael Tanen Caroline Cilissen Marina De Smet Inge de Lepeleire Kristien Van Dyck Amy Q Wang Wei Zeng Michael J Davies Wesley Tanaka Jens J Holst Carolyn F Deacon Keith M Gottesdiener John A Wagner

CONTEXT In response to a meal, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are released and modulate glycemic control. Normally these incretins are rapidly degraded by dipeptidyl peptidase-4 (DPP-4). DPP-4 inhibitors are a novel class of oral antihyperglycemic agents in development for the treatment of type 2 diabetes. The degree of DPP-4 inhibition and th...

2009
Jonathan K Reynolds

Janumet(TM,) a fixed dose combination of sitagliptin/metformin HCL manufactured by Merck Pharmaceuticals, has received US Food and Drug Administration approval for treatment of patients with type 2 diabetes, that are inadequately controlled, either by sitagliptin or metformin alone or together in free-dose combination form. Sitagliptin, an inhibitor of the enzyme DDP-4, assists patients with ty...

2016
Nouf M Al-Rasheed Nawal M Al-Rasheed Iman H Hasan Maha A Al-Amin Hanaa N Al-Ajmi Ayman M Mahmoud

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, has been reported to promote cardioprotection in diabetic hearts by limiting hyperglycemia and hyperlipidemia. However, little is known about the involvement of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway modulation in the cardioprotective effects of sitagliptin. The current study aimed to investigate the ...

Journal: :The Cochrane database of systematic reviews 2008
B Richter E Bandeira-Echtler K Bergerhoff C L Lerch

BACKGROUND In type 2 diabetes mellitus there is a progressive loss of beta-cell function. One new approach yielding promising results is the use of the orally active dipeptidyl peptidase-4 (DPP-4) inhibitors like sitagliptin and vildagliptin. OBJECTIVES To assess the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. SEARCH STRATEGY Studies were obtained from...

2015
Md. Ashraful Alam Mohammed Riaz Hasan Chowdhury Preeti Jain Md. Abu Taher Sagor Hasan Mahmud Reza

BACKGROUND Hyperglycemia and insulin resistance often develop cardiovascular and nephrological dysfunction in diabetic patients. Sitagliptin is used to treat diabetes and showed potential benefit in lowering increased blood glucose level in diabetes. This investigation reports the effect of sitagliptin treatment on oxidative stress in kidney and heart of 2K1C rats. METHODS Male Long Evans rat...

Journal: :The Journal of clinical endocrinology and metabolism 2016
Sumit R Majumdar Robert G Josse Mu Lin Dean T Eurich

CONTEXT Type 2 diabetes and osteoporosis are both common, chronic, and increase with age, whereas type 2 diabetes is also a risk factor for major osteoporotic fractures (MOFs). However, different treatments for type 2 diabetes can affect fracture risk differently, with metaanalyses showing some agents increase risk (eg, thiazolidinediones) and some reduce risk (eg, sitagliptin). OBJECTIVE To ...

2017
Ryo Kodera Kenichi Shikata Akihiko Nakamura Satoru Okazaki Ryo Nagase Tatsuaki Nakatou Shigeru Haisa Kazuyuki Hida Katsuhiro Miyashita Hirofumi Makino

Objective Dipeptidyl peptidase-4 (DPP-4) inhibitors are the most frequently prescribed oral hypoglycemic agents in Japan. Although a relationship between the efficacy of DPP-4 inhibitors and the body mass index (BMI) has been reported, this relationship is controversial. We investigated whether the BMI value affects the glucose-lowering efficacy of sitagliptin in obese Japanese patients with ty...

2013
Kwon Wook Joo Sejoong Kim Shin-young Ahn Ho Jun Chin Dong-Wan Chae Jeonghwan Lee Jin Suk Han Ki Young Na

BACKGROUND The inhibition of dipeptidyl peptidase (DPP) IV shows protective effects on tissue injury of the heart, lung, and kidney. Forkhead box O (FoxO) transcriptional factors regulate cellular differentiation, growth, survival, the cell cycle, metabolism, and oxidative stress. The aims of this study were to investigate whether the DPP IV inhibitor sitagliptin could attenuate kidney injury a...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید